Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$10.73
-1.4%
$8.66
$5.92
$11.11
$2.25B1.083.01 million shs3.22 million shs
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$1.75
-4.3%
$2.80
$1.64
$12.51
$584.39M1.068.68 million shs7.67 million shs
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
$29.52
+2.2%
$35.28
$27.12
$60.90
$1.77B2.54977,013 shs1.25 million shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$4.86
-6.4%
$5.50
$4.32
$14.45
$671.84M1.361.39 million shs2.40 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
0.00%+1.32%+20.16%+25.64%+66.10%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
0.00%-1.57%-49.94%-56.63%-80.27%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
0.00%+4.46%-24.77%-20.45%-29.55%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
0.00%+8.00%-21.10%-38.64%-52.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
4.4447 of 5 stars
4.41.00.04.24.01.70.6
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
4.6724 of 5 stars
4.31.00.04.22.84.21.3
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
4.3375 of 5 stars
4.41.00.04.44.20.80.6
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.9883 of 5 stars
3.41.00.00.03.33.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
2.89
Moderate Buy$16.5654.29% Upside
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
2.50
Moderate Buy$13.30659.13% Upside
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4070.73% Upside
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.86
Moderate Buy$32.86576.07% Upside

Current Analyst Ratings Breakdown

Latest VIR, IOVA, TWST, and BCRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
5/16/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$17.00 ➝ $2.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $8.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $10.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00
5/12/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/12/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.00 ➝ $14.00
5/9/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/9/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Perform
5/9/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $25.00
5/9/2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$503.49M4.46N/AN/A($2.22) per share-4.83
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$212.68M2.75N/AN/A$2.28 per share0.77
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
$347.68M5.09N/AN/A$7.64 per share3.86
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$14.30M46.98N/AN/A$11.82 per share0.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-$226.54M-$0.26N/AN/AN/A-30.01%N/A-24.06%8/4/2025 (Estimated)
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$444.04M-$1.24N/AN/AN/A-451.25%-58.43%-45.48%8/7/2025 (Estimated)
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-59.76%-32.69%-25.25%8/1/2025 (Estimated)
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$615.06M-$4.22N/AN/AN/A-678.40%-36.71%-31.00%7/30/2025 (Estimated)

Latest VIR, IOVA, TWST, and BCRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.25-$0.36-$0.11-$0.36$83.40 million$49.32 million
5/7/2025Q1 2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.83-$0.88-$0.05-$0.88$8.59 million$3.03 million
5/5/2025Q2 2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/AN/AN/AN/AN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/AN/AN/AN/AN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/A
2.78
2.73
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/A
4.22
3.90
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
0.03
4.96
4.62
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/A
8.94
8.94

Institutional Ownership

CompanyInstitutional Ownership
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
85.88%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
77.03%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
65.32%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
530209.25 million197.19 millionOptionable
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
500333.93 million267.90 millionOptionable
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
99059.92 million57.86 millionOptionable
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
580138.24 million116.24 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioCryst Pharmaceuticals stock logo

BioCryst Pharmaceuticals NASDAQ:BCRX

$10.73 -0.15 (-1.38%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$10.75 +0.02 (+0.19%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Iovance Biotherapeutics stock logo

Iovance Biotherapeutics NASDAQ:IOVA

$1.75 -0.08 (-4.26%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$1.75 0.00 (-0.11%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$29.52 +0.63 (+2.18%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$29.30 -0.22 (-0.75%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Vir Biotechnology stock logo

Vir Biotechnology NASDAQ:VIR

$4.86 -0.33 (-6.36%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$4.94 +0.08 (+1.65%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.